



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

Visit IR website [↗](#)  
Sign-up for e-mail alerts [↗](#)

**NASDAQ: CELG**

Last Trade:	79.77
Trade Time:	4:00 PM ET Jun 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	74.13 - 147.17
Volume	314

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jun 19, 2018 [Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi](#)
- Jun 3, 2018 [Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel \(JCAR017\) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO](#)
- Jun 3, 2018 [Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab \(R<sup>2</sup>\) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018](#)
- Jun 1, 2018 [Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting](#)
- Jun 1, 2018 [Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of](#)

**Financials** [\[ View all \]](#)

- Feb 7, 2018 [Annual Report \(10-K\)](#)
- Apr 30, 2018 [Proxy Statement \(DEF 14A\)](#)
- May 4, 2018 [Quarterly Report \(10-Q\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)

